A Facebook post credits Novo Nordisk's GLP-1 drugs with strong results in obesity and type 2 diabetes, plus lower risk of other conditions.
Recap by typeshit. Post by Facebook on Facebook.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
Polish pharmacy platform GdziePoLek says, citing the manufacturer, that the first Oral Wegovy shipment should arrive soon. No exact launch date is set yet.
A short clip from Dr. Reese pushing back on the rush toward peptides as an easy shortcut, with little detail beyond that.
Novo Nordisk is lowering what Wegovy costs in China, a fresh move in the race for the country's obesity drug market. No figures were given.
Loading…